New migraine drug! Lilly Emgality Treatment For Hair/Chronic Migraines Significantly Reduces Pain Frequency, Duration, Severity!

, June 18, 2020/
/
has released a new analysis of the migraine drug Egalezumab for the treatment of seizure migraine (episodic migraine, EM) and chronic migraine (chronic migraine, CM)The data showed that Emgality reduced the overall pain burden on patients, a patient-centered indicator that combines the frequency, duration, and pain severity of migraines per monthIn addition, the overall pain burden was significantly correlated with the patient's function and quality of lifenote, Emgality is the first and only preventive CGRP drug for migraines evaluated in this way, providing a more complete picture of how Emgality reduces the frequency, duration and severity of migraines"The overall pain burden exceeds the current limited method of describing migraines," said DrGudarz Davar, vice president of neurobiology development at Lilly,We are pleased that Emgality reduces the combined effects of migraine frequency, duration and pain severityWe believe that migraines from the perspective of the overall pain burden provide a more comprehensive way for migraine sufferers and clinicians to discuss individual pain experiences"
the post-mortem analysis of Emgality and Placebo used data from three randomized, double-blind studies on seizure migraines (two combined six-month studies - EVOLVE-1 and EVOLVE-2; Emgality n?435, placebon s 872) and chronic migraines (a three-month study - RETAIN; Emgal n 273, placebon ? 535), respectivelyPatients use electronic journals to report their headache frequency, duration and severityMultiply the number of migraine hours recorded on each migraine day with the severity of the pain (0-none, 1-mild, 2-moderate, 3-severe) and combine these composite measurements with the number of migraine days in a month to calculate the total pain burden per month as a severity-weighted durationcompare the average monthly average of the total pain load and baseline in the Emgality group and the placebo groupCompared to the placebo group, the monthly weighted pain severity of patients in the Emgality group was significantly lower than the baseline (p 0.0001 per comparison)In the onset of migraines, the average per-patient weighted number of pain severity in the Emgality group decreased by 68.6 hours per month compared to the baseline group, while the patients in the placebo group decreased by 36.2 hours per month (average difference: 32.3 hours, 95% CI: 24.2 to 40.3)In chronic migraines, the average pain severity weighted hours per month in the Emgality group were 102.6 hours less than in the baseline group, while the monthly pain severity weighted hours in the placebo group were 44.4 hours less than in the baseline group (average difference: 58.2 severity weighted hours, 95% CI: 37.1 to 79.3)"The effects of migraines are profound, and individual management is more than just how many days a person experiences a month," said Jessica Ailani, M.D., professor of clinical neurology at Georgetown University Hospital inand director of the MedStar Georgetown Headache CenterThe overall pain burden is a more comprehensive measure that provides us and our patients with a deeper understanding of their pain descriptionAs a clinician, I am pleased that Emgality can help my patients achieve their preventive treatment goalsI'm excited that the results of this study show that Emgality has a positive effect on the cumulative burden of migraine frequency, duration and pain severity"
migraines are the third most common disease and the sixth most common disease in the world, a common chronic neurovascular disease characterized by recurrent severe headaches, mostly on the sideIt is estimated that globally, the total number of migraine sufferers is more than 1 billion, about 90% of which are onset migraines (Em), characterized by up to 14 days of migraine per month, and the remaining 10% are chronic migraines (CM), characterized by at least 15 days of headache per month, of which 8 or more are migraines, with a duration of more than 3 monthsAt present, there is no drug to cure migrainesThe World Health Organization (WHO) has ranked migraines as one of the 10 most disabling diseases, with migraine sufferers more likely to experience depression, anxiety, sleep disorders, other pain and fatigue than other populationscalcitonin-related gene peptide (CGRP) is a neuropeptide that has been shown to be released during a migraine attack and is considered a cause of migraine attacksAt present, CGRP and its receptors have become a hot target for the development of migraine drugsso far, four mono-resistant migraine treatments targeting CGRP and its receptors have been on the market, including: Lilly
Emgality (Targeting CGRP), Amgen/
Novartis
Aimovig (Target INGRP), Lingbei Vyepti (Target CGRP), Teva Ajovy (Target CGRP) On medication, Both Emgality and Aimovig are daily subcutaneous injections, Ajovy can be injected once a month or every 3 months, and Vyepti has intravenous infusions every 3 months among , Emgality was approved by the U.S FDA in September 2018 for preventive treatment of migraines in adults In June 2019, Emgality was approved by the U.S FDA for the treatment of adult seizures of episode disorder (ECH) noteworthy, Emgality was the first drug to treat ECH and the first CGRP antibody to treat two different headache disorders (BioValleyBioon.com) original origins: Emgality® S S Reduction in Frequency, Duration, and Pain Severity in Patients with Episodic and Chronic Migraine .